The special access program, as you've said, is intended for emergency and life-threatening conditions. An individual physician comes in and makes a request for an individual patient and it's assessed as such. When requests come in, we do look at the information that the physician has provided and there are assurances that the physician has spoken to the patient about the potential risks and benefits, and then they're assessed on a case-by-case basis.
Comparing the two products, hydromorphone is a marketed product, but it is not marketed for that use, and diacetylmorphine has also a body of evidence that supports its use in terms of chronic relapsing opioid dependence and it has been used in a number of different countries.
As with any request to the special access program, we would look at that individual's information and the request that's being made, to make sure that it fulfills the criteria of the special access program and that it's reasonable. In some cases, you're right, in that we have authorized the use of diacetylmorphine. It has to be when all other treatments that could be applied have unfortunately failed, so it's a very small percentage of patients.